Literature DB >> 3965177

Reduced regional myocardial perfusion in the presence of pharmacologic vasodilator reserve.

J M Canty, F J Klocke.   

Abstract

To determine whether reductions in regional myocardial perfusion at reduced coronary arterial pressures reliably indicate maximal vasodilation of the distal vasculature, coronary autoregulation was studied in open-chest dogs at heart rates of approximately 60 beats/min, a level at which metabolic demand, time-averaged systolic compressive forces, and transmural vasodilator reserve approximate those found under usual resting conditions. Circumflex pressure was controlled with a programmable pressure source. Regional circumflex inflow was 0.56 +/- 0.04(SEM) ml . min-1 . g-1 when circumflex pressure equaled spontaneous aortic pressure and fell to 0.34 +/- 0.02 ml . min-1 . g-1 when circumflex pressure was reduced to 35 mm Hg. Reductions were similar in each myocardial layer, with endocardial flow falling from 0.68 +/- 0.04 to 0.39 +/- 0.03 ml . min-1 . g-1. During adenosine-induced vasodilation at 35 mm Hg, full-thickness and endocardial flows rose to 0.92 +/- 0.08 and 1.07 +/- 0.10 ml . min-1 . g-1, respectively. When coronary pressure was reduced to 25 mm Hg and autoregulation was again operative, full-thickness and endocardial flows fell to 0.28 +/- 0.03 and 0.28 +/- 0.04 ml . min-1 . g-1. During adenosine vasodilation at 25 mm Hg endocardial flow did not increase significantly but epicardial reserve remained present. These results indicate that significant reductions in regional myocardial perfusion can occur before pharmacologic vasodilator reserve is exhausted. In the absence of tachycardia, endocardial vasodilator reserve can persist to coronary pressures less than 35 mm Hg, but is ordinarily exhausted before epicardial vasodilator reserve.

Entities:  

Mesh:

Year:  1985        PMID: 3965177     DOI: 10.1161/01.cir.71.2.370

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

Review 1.  Evidence for aggressive blood pressure-lowering goals in patients with coronary artery disease.

Authors:  Monisankar Roy; Noman Mahmood; Clive Rosendorff
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

2.  Pharmacological vasodilatation in the assessment of pressure-derived collateral flow index.

Authors:  D Perera; S Patel; L Blows; E Tomsett; M Marber; S Redwood
Journal:  Heart       Date:  2006-08       Impact factor: 5.994

Review 3.  The renin-angiotensin system and coronary vasomotion.

Authors:  G Ertl; K Hu; W R Bauer; B Bauer
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

4.  Interventricular redistribution of myocardial blood flow during metabolic vasodilation.

Authors:  B D Guth; R Schulz; E Thaulow
Journal:  Pflugers Arch       Date:  1991-01       Impact factor: 3.657

5.  Why is the subendocardium more vulnerable to ischemia? A new paradigm.

Authors:  Dotan Algranati; Ghassan S Kassab; Yoram Lanir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-17       Impact factor: 4.733

Review 6.  Heterogeneity of myocardial blood flow.

Authors:  J I Hoffman
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

7.  Alpha 1-adrenergic blockade reduces exercise-induced regional myocardial ischemia in dogs.

Authors:  B D Guth; T Miura; E Thaulow; G Heusch; J Ross
Journal:  Basic Res Cardiol       Date:  1993 May-Jun       Impact factor: 17.165

Review 8.  The relationship between regional blood flow and contractile function in normal, ischemic, and reperfused myocardium.

Authors:  G Heusch
Journal:  Basic Res Cardiol       Date:  1991 May-Jun       Impact factor: 17.165

9.  Coronary collateral reserve during exercise induced ischemia in swine.

Authors:  F C White; D M Roth; C M Bloor
Journal:  Basic Res Cardiol       Date:  1989 Jan-Feb       Impact factor: 17.165

Review 10.  Role of calcium channel blockers in experimental exercise-induced ischemia.

Authors:  E Thaulow; B D Guth; J Ross
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.